Scope of the Study
Codeine phosphate is an analgesic indicated for the relief of mild to moderate pain. It is an alkaloid obtained from opium or prepared from morphine by methylation and occurs as white crystals. It used as similar to Morphine but it is much less potent as an analgesic and has only mild sedative effects.
The market study is being classified by Type (Extracted from Opium and Synthesized by Morphine), by Application (Narcotic Analgesic, Antitussive and Others) and major geographies with country level break-up.
Macfarian Smith (United Kingdom), Francopia (France), Noramco, Inc. (United States), Weifa (Norway), Mallinckrodt (United Kingdom), GSK (United Kingdom), Alkaloida (Hungary), Tasmanian Alkaloids (Australia), Fine Chemicals Inc. (Canada) and Sinopharm Group (China) are some of the key players profiled in the study.
Research Analyst at AMA predicts that United Kingdom Players will contribute to the maximum growth of Global Codeine Phosphate market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Codeine Phosphate market by Type, Application and Region.
On the basis of geography, the market of Codeine Phosphate has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- High Demand for Pain Reliever
- Increasing Demand from Hospitals and Clinics
- Growing Awareness about Healthy Lifestyle
- Growing Healthcare Industry
- Rising Number of Pharmacies
- Growing Demand from Online Customers
- Stringent Rules and Regulations
Market Leaders and their expansionary development strategies
In December 2018, GlaxoSmithKline plc has reached an agreement with Pfizer Inc to combine their consumer health businesses into a new world-leading Joint Venture. GSK will have a majority controlling equity interest of 68% and Pfizer will have an equity interest of 32% in the Joint Venture.
Key Target AudienceCodeine Phosphate Manufacturers, Raw Material Suppliers, Distributors and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase